The National Institute for Health and Care Excellence, which provides drug guidance for the NHS, said there are some side effects that can be seen commonly and include an abnormal appetite, ...
("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company developing precision drug delivery ... efficacy of EP-104GI as a treatment for eosinophilic esophagitis ...
In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.